|
17.12.2014 08:00:49
|
Medigene to participate in three international conferences in January
Medigene AG / Medigene to participate in three international conferences in January . Processed and transmitted by Nasdaq OMX Corporate Solutions. The issuer is solely responsible for the content of this announcement.
Press Release
Martinsried/Munich, 17 December, 2014. Medigene AG (MDG1, Frankfurt, Prime Standard) announces its participation in three upcoming international investment, scientific and business development conferences:
-
J.P. Morgan 33rd Annual Healthcare Conference
Date: 12 - 15 January 2015
Location: San Francisco, USA
-
Biotech Showcase - 7th Annual Conference
Date: 12 - 14 January 2015
Location: San Francisco, USA
Company Presentation on 13 January 10 am (PST)
-
Phacilitate Immunotherapie Forum 2015
Date: 26 - 28 January 2015
Location: Washington D.C., USA
Prof. Dolores J. Schendel, Chief Scientific Officer, Medigene AG will chair the following events:
- 15-01-27: Seminar "Tailoring immunotherapies for patients with different stages of prostate cancer"
- 15-01-28: Panel discussion "What advancements can we expect in the short and longer term to optimize the specificity and selectivity of the next generation immunotherapeutic agents to deal with the diversity that is the tumor?"
Medigene AG is a publicly listed (Frankfurt: MDG1, prime standard) biotechnology company headquartered in Martinsried near Munich, Germany. Medigene concentrates on the development of personalized T cell immunotherapies with a focus on haematological malignancies. Medigene is the first German biotech company to have revenues from a marketed product, which is distributed by commercial partner companies. Medigene has advanced drug candidates which are licensed to partners and additional candidates in clinical development. The company is developing highly innovative treatment platforms concentrating on cancer and autoimmune diseases. For more information, please visit www.medigene.com.
This press release contains forward-looking statements representing the opinion of Medigene as of the date of this release. The actual results achieved by Medigene may differ significantly from the forward-looking statements made herein. Medigene is not bound to update any of these forward-looking statements. Medigene® EndoTAG® and Veregen® are registered trademarks of Medigene AG. These trademarks may be owned or licensed in select locations only.
Contact Medigene
Julia Hofmann, Anja Clausnitzer
Tel.: +49 - 89 - 20 00 33 - 33 01
Email: investor@medigene.com
To unsubscribe from the press release distribution list, please visit: http://www.medigene.de/unsubscribe
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Medigene AG via Globenewswire
--- End of Message ---
Medigene AG
Lochhamer Strasse 11 Martinsried / München Germany
WKN: A1X3W0;ISIN: DE000A1X3W00;
Listed: Freiverkehr in Börse Stuttgart,
Freiverkehr in Hanseatische Wertpapierbörse zu Hamburg,
Freiverkehr in Börse Berlin,
Freiverkehr in Börse Düsseldorf,
Freiverkehr in Bayerische Börse München,
Freiverkehr in Niedersächsische Börse zu Hannover,
Prime Standard in Frankfurter Wertpapierbörse,
Regulierter Markt in Frankfurter Wertpapierbörse;
Der finanzen.at Ratgeber für Aktien!
Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu Medigenemehr Nachrichten
Analysen zu Medigenemehr Analysen
Nachrichten
ETF-Sparplan
Oskar ist der einfache und intelligente ETF-Sparplan. Er übernimmt die ETF-Auswahl, ist steuersmart, transparent und kostengünstig.